Introduction
Semaglo Tablet 3 mg is a glucagon-like peptide-1 (GLP-1) receptor agonist used for managing type 2 diabetes and for weight management. It mimics the action of the natural GLP-1 hormone, which helps control blood sugar levels and appetite.
Uses
Semaglo Tablet 3 mg is used for:
- Controlling blood glucose levels in adults with type 2 diabetes, often in conjunction with diet and exercise.
- Weight management in adults with obesity or overweight, when combined with a reduced-calorie diet and increased physical activity.
| Brand Name | Semaglo |
|---|---|
| Type | Tablet |
| Weight | 3 mg |
| Generic | Semaglutide |
| Manufacturer | Ziska Pharmaceuticals Ltd. |
| Available in | English বাংলা |
Mechanism of Action
Semaglo Tablet 3 mg works by activating GLP-1 receptors, which leads to:
- Increased insulin secretion in response to meals.
- Decreased glucagon release.
- Slowed gastric emptying.
- Reduced appetite.
How Long Does It Take to Work?
The effects of semaglutide can be observed within a few weeks of starting treatment. Blood glucose levels typically start to improve within 1-2 weeks, while significant weight loss may be seen within a few months. Maximum efficacy is often achieved after 3-6 months of therapy.
Absorption
Semaglo Tablet 3 mg is administered subcutaneously and is well absorbed, with peak plasma concentrations occurring approximately 1-3 days after injection. Its bioavailability is approximately 89% following subcutaneous injection.
Route of Elimination
Semaglo Tablet 3 mg is primarily metabolized in the liver through proteolytic cleavage and is then excreted mainly through the urine. It is not significantly metabolized by the kidneys, so renal impairment does not significantly affect its clearance.
Dosage
For Diabetes:Semaglutide Tablet: Take Semaglutide at least 30 minutes before the first food, beverage, or other oral medications of the day with no more than 4 ounces (118 ml) of plain water only.
- Starter Dose: Start Semaglutide with 3 mg once daily for 30 days
- Maintenance Dose: After 30 days on the 3 mg dose, increase the dose to 7 mg once daily
- For Additional Glycemic Control: If additional glycemic control is needed after at least 30 days on the 7 mg dose, the dose can be increased to 14 mg once daily
Switching patients between Semaglutide injection and Semaglutide tablet-
- Patients treated with once weekly Semaglutide injection 0.5 mg subcutaneous injection can be transitioned to Semaglutide 7 mg or 14 mg tablet. Patients can start Semaglutide tablet up to 7 days after their last injection of Semaglutide injection. There is no equivalent dose of Semaglutide tablet for Semaglutide injection 1 mg
- Patients treated with Semaglutide 14 mg tablet daily can be transitioned to Semaglutide subcutaneous injection 0.5 mg once weekly. Patients can start Semaglutide injection the day after their last dose of Semaglutide tablet.
For Obesity: The starting dose is 0.25 mg Semaglutide once weekly for 4 weeks subcutaneously. If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks. If patients do not tolerate the maintenance dose 2.4 mg, the dose can be temporarily decreased to 1.7 mg once weekly for maximum 4 weeks. After 4 weeks increase the dose to 2.4 mg. Weekly doses higher than 2.4 mg is not recommended. Semaglutide is to be administered once weekly at any time of the day with or without meals. Semaglutide is to be injected subcutaneously in the abdomen, thigh or in upper arm. The injection site can be changed without dose adjustment. Semaglutide should not be administered intravenously or intramuscularly. The day of weekly administration can be changed if necessary as long as the time between two doses is at least 2 days (>48 hours). After selecting a new dosing day, once weekly dosing should be continued.
The dosage of semaglutide depends on the indication:
- For type 2 diabetes: Start with 0.25 mg subcutaneously once weekly for the first 4 weeks, then increase to 0.5 mg once weekly. Depending on blood glucose control, the dose may be further increased to 1.0 mg once weekly.
- For weight management: Start with 0.25 mg subcutaneously once weekly, gradually increasing to 1.0 mg once weekly. The dose may be further increased to 2.0 mg or 2.4 mg once weekly, depending on the patient's response and tolerance.
Administration
Semaglo Tablet 3 mg is administered as a subcutaneous injection in the abdomen, thigh, or upper arm. It is given once weekly at any time of day, with or without food. Injection sites should be rotated to avoid irritation.
Side Effects
Common side effects include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Pancreatitis
- Thyroid tumors
- Severe allergic reactions
Toxicity
Acute toxicity is rare but may include severe gastrointestinal symptoms such as persistent nausea or vomiting. Chronic use may be associated with an increased risk of thyroid cancer and pancreatitis. Regular monitoring and dose adjustments are important.
Precautions
Precautions include:
- Monitoring for signs of pancreatitis and thyroid tumors.
- Periodic assessment of renal function.
- Use cautiously in patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Interaction
Semaglo Tablet 3 mg may interact with:
- Other glucose-lowering agents, which may increase the risk of hypoglycemia.
- Medications affecting gastrointestinal motility or absorption.
Disease Interaction
Use semaglutide with caution in:
- Patients with a history of pancreatitis or thyroid disorders.
- Patients with severe renal or gastrointestinal disorders.
Drug Interaction
Semaglo Tablet 3 mg may interact with:
- Antidiabetic drugs, potentially requiring dose adjustments to prevent hypoglycemia.
- Drugs that affect gastrointestinal motility or absorption.
Food Interactions
Semaglo Tablet 3 mg does not have specific food interactions. However, maintaining a balanced diet is important as changes in dietary habits can impact blood glucose levels and weight management.
Pregnancy Use
The use of semaglutide during pregnancy is not recommended unless clearly needed. Its safety in pregnant women is not well established, and it should only be used if the potential benefits outweigh the risks.
Lactation Use
Semaglo Tablet 3 mg is not recommended for use during lactation. It is unknown whether semaglutide is excreted in breast milk or its effects on the nursing infant.
Acute Overdose
In the event of an acute overdose, symptoms may include severe nausea, vomiting, and dehydration. Management includes supportive care, monitoring, and symptomatic treatment.
Contraindication
Semaglo Tablet 3 mg is contraindicated in:
- Patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
- Patients with a history of severe hypersensitivity to semaglutide or any of its components.
Use Direction
Semaglo Tablet 3 mg should be used as prescribed, following the recommended dosage and administration instructions. Regular monitoring of blood glucose levels and weight is essential to assess efficacy and adjust treatment as necessary.
Storage Conditions
Semaglo Tablet 3 mg should be stored in the refrigerator at 2-8°C (36-46°F). Once in use, it can be kept at room temperature (up to 30°C or 86°F) for up to 56 days. Protect from light and keep out of reach of children.
Volume of Distribution
The volume of distribution of semaglutide is approximately 15 L, indicating its distribution throughout body tissues and fluids.
Half Life
The half-life of semaglutide is approximately 1 week, which supports its once-weekly dosing regimen.
Clearance
Semaglo Tablet 3 mg is primarily metabolized by the liver and is excreted mainly through the urine. The clearance rate is not significantly affected by renal impairment.
See in details version Semaglo Tablet 3 mg also Semaglo Tablet 3 mg in bangla
Social card
Some Frequently Asked Questions About Semaglo Tablet 3 mg
Dr. Nafisa Anwar Mariana
Gynecology, Obstetrics, Infertility, Normal Delivery Specialist & Surgeon
